Next Article in Journal
Factors Affecting the Acceptance of Pandemic Influenza A H1N1 Vaccine amongst Essential Service Providers: A Cross Sectional Study
Article Menu

Export Article

Open AccessReview
Vaccines 2013, 1(1), 1-16;

Peptide Vaccine Therapy in Colorectal Cancer

Research Department of General Surgery, Division of Surgery and Interventional Science, UCL Medical School, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
Author to whom correspondence should be addressed.
Received: 6 July 2012 / Revised: 15 August 2012 / Accepted: 16 August 2012 / Published: 24 August 2012
Full-Text   |   PDF [327 KB, uploaded 18 September 2012]   |  


Colorectal cancer is the third most common cause of cancer-related deaths and the second most prevalent (after breast cancer) in the western world. High metastatic relapse rates and severe side effects associated with the adjuvant treatment have urged oncologists and clinicians to find a novel, less toxic therapeutic strategy. Considering the limited success of the past clinical trials involving peptide vaccine therapy to treat colorectal cancer, it is necessary to revise our knowledge of the immune system and its potential use in tackling cancer. This review presents the efforts of the scientific community in the development of peptide vaccine therapy for colorectal cancer. We review recent clinical trials and the strategies for immunologic monitoring of responses to peptide vaccine therapy. We also discuss the mechanisms underlying the therapy and potential molecular targets in colon cancer. View Full-Text
Keywords: peptide vaccine therapy; colorectal cancer; EphA2; survivin; SART3; CEA and MUC-1 peptide vaccine therapy; colorectal cancer; EphA2; survivin; SART3; CEA and MUC-1

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Bartnik, A.; Nirmal, A.J.; Yang, S.-Y. Peptide Vaccine Therapy in Colorectal Cancer. Vaccines 2013, 1, 1-16.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top